INGN logo

Inogen, Inc.NasdaqGS:INGN Stock Report

Market Cap US$209.6m
Share Price
US$7.75
My Fair Value
US$11
29.5% undervalued intrinsic discount
1Y-39.1%
7D2.6%
Portfolio Value
​
View

Inogen, Inc.

NasdaqGS:INGN Stock Report

Market Cap: US$209.6m

Inogen (INGN) Stock Overview

A medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. More details

INGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 70.6% below our estimate of its fair value

Trading at good value compared to peers and industry

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


INGN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

INGN logo
Inogen

Pricing Pressures And Rivals Will Erode Portable Oxygen Margins

Key Takeaways Heightened pricing pressures, commoditization risks, and more low-cost competitors threaten Inogen's market share, margins, and ability to sustain growth. Shifting technology trends, declining gross margins, and stricter regulatory requirements may further erode profitability without significant innovation or efficiency gains.
View narrative
US$7.00
FV
10.7% overvalued intrinsic discount
6.09%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
13 days ago author updated this narrative
INGN logo
Inogen

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Key Takeaways Growing demand for home respiratory care and a diversifying product portfolio position the company for sustained market expansion and top-line growth. Digital integration, operational optimization, and new product innovation are driving higher margins, recurring revenue, and support for long-term earnings growth.
View narrative
US$11.00
FV
29.5% undervalued intrinsic discount
6.54%
Revenue growth p.a.
0users have liked this narrative
3users have commented on this narrative
5users have followed this narrative
10 days ago author updated this narrative
INGN logo
Inogen

Aging Global Population And At-Home Care Will Boost Market Demand

Key Takeaways Portfolio expansion with bundled oxygen solutions and new product launches positions Inogen for sustained, accelerated growth and broader market leadership. Integration of digital health and international expansion supports higher customer value, recurring high-margin revenue, and substantial long-term profit potential.
View narrative
US$14.00
FV
44.6% undervalued intrinsic discount
6.48%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4 days ago author updated this narrative
View Stock Community

Inogen, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Inogen
Historical stock prices
Current Share PriceUS$7.75
52 Week HighUS$13.33
52 Week LowUS$5.70
Beta1.72
1 Month Change13.97%
3 Month Change17.07%
1 Year Change-39.07%
3 Year Change-72.96%
5 Year Change-74.36%
Change since IPO-48.84%

Recent News & Updates

Recent updates

Inogen: Still Breathing, But Margin Pressures Persist

Jun 16

Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report

May 10
Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report
User avatar

Yuwell Collaboration Will Open Chinese Respiratory Market

Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.

Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

Mar 08
Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

A Volatile Share Price Masks Some Of The Progress At Inogen

Mar 01

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Feb 28
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Jan 22
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Inogen: Upside Seems Limited After Big Move Up

Sep 24

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 16
Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Inogen: Improving, But Still Struggling For Air

Jul 01

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

May 22
Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Apr 13

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Mar 01
Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Feb 01
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Is Inogen (NASDAQ:INGN) In A Good Position To Deliver On Growth Plans?

Oct 06
Is Inogen (NASDAQ:INGN) In A Good Position To Deliver On Growth Plans?

Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business

Jun 21
Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business

Is Inogen, Inc. (NASDAQ:INGN) Worth US$13.3 Based On Its Intrinsic Value?

Mar 14
Is Inogen, Inc. (NASDAQ:INGN) Worth US$13.3 Based On Its Intrinsic Value?

Companies Like Inogen (NASDAQ:INGN) Can Afford To Invest In Growth

Oct 27
Companies Like Inogen (NASDAQ:INGN) Can Afford To Invest In Growth

Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price

Sep 20
Inogen, Inc.'s (NASDAQ:INGN) Intrinsic Value Is Potentially 64% Above Its Share Price

Inogen: Structural, Supply Chain Headwinds Remain

Sep 13

Shareholder Returns

INGNUS Medical EquipmentUS Market
7D2.6%2.0%0.5%
1Y-39.1%6.1%15.9%

Return vs Industry: INGN underperformed the US Medical Equipment industry which returned 6.1% over the past year.

Return vs Market: INGN underperformed the US Market which returned 15.9% over the past year.

Price Volatility

Is INGN's price volatile compared to industry and market?
INGN volatility
INGN Average Weekly Movement7.4%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.5%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: INGN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: INGN's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001766Kevin R. Smithwww.inogen.com

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories.

Inogen, Inc. Fundamentals Summary

How do Inogen's earnings and revenue compare to its market cap?
INGN fundamental statistics
Market capUS$209.56m
Earnings (TTM)-US$26.05m
Revenue (TTM)US$343.47m
0.6x
P/S Ratio
-8.0x
P/E Ratio

Is INGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INGN income statement (TTM)
RevenueUS$343.47m
Cost of RevenueUS$188.13m
Gross ProfitUS$155.35m
Other ExpensesUS$181.39m
Earnings-US$26.05m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.96
Gross Margin45.23%
Net Profit Margin-7.58%
Debt/Equity Ratio0%

How did INGN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/25 10:42
End of Day Share Price 2025/08/22 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inogen, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anderson SchockB. Riley Securities, Inc.
Robert MarcusJ.P. Morgan
Matthew MishanKeyBanc Capital Markets Inc.